Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × regorafenib × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 5 Sarcoma 2 Esophageal Neoplasms 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Malignant Tumors 1 Small Cell Lung Carcinoma 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Liver Metastasis Colon Cancer 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Merkel Cell 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Specimen Handling 32 Biopsy 30 Magnetic Resonance Spectroscopy 21 pembrolizumab 18 Nivolumab 12 trastuzumab deruxtecan 9 Paclitaxel 9 Pemetrexed 8 Cisplatin 8 Carboplatin 8 Taxes 7 Leucovorin 6 Irinotecan 6 Ipilimumab 6 Gemcitabine 6 Fulvestrant 6 Fluorouracil 6 Cetuximab 6 Capecitabine 6 130-nm albumin-bound paclitaxel 6 X-Rays 5 Radiosurgery 5 Oxaliplatin 5 Cyclophosphamide 5 abemaciclib 4 Trastuzumab 4 Drug Therapy 4 Doxorubicin 4 tislelizumab 3 talazoparib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01900743 2026-03-13

REGO-SARC

Centre Oscar Lambret

Phase 2 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡